sponsored
PatientsVille.com Logo

PatientsVille

Thyrogen Medical Research Studies

Up-to-date List of Thyrogen Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Thyrogen Medical Research Studies

Rank Status Study
1 Recruiting Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
Condition: Thyroid Carcinoma
Interventions: Drug: Vemurafenib;   Device: serial 124I PET/CT;   Drug: thyrotropin alpha
Outcome Measures: Response;   objective response rate (ORR);   safety
2 Recruiting Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism
Condition: Infertility
Interventions: Drug: Lutropin alfa;   Drug: Follitropin alfa and Lutropin alfa
Outcome Measures: number of follicles;   Size of follicle;   Endometrial thickness;   number of oocytes retrieved;   Fertilization rate;   Biochemical pregnancy rate;   Clinical pregnancy rate;   Implantation rate
3 Unknown  Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma Patients
Condition: Thyroid Cancer
Intervention: Drug: Thyrogen, thyroid hormone withdrawal, iode 131
Outcome Measures: the rate of successful postoperative thyroid ablation;   the rate of long-term complications;   specific toxicities;   management costs (hospitalization, diagnosis tests and sick leave);   quality of life and utility
4 Not yet recruiting Markers of Pubertal Suppression During Therapy for Precocious Puberty
Condition: Central Precocious Puberty
Intervention:
Outcome Measure: Sensitivity and specificity of free alpha subunit of pituitary glycoprotein to identify subjects with appropriate pubertal suppression.
5 Recruiting A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)
Condition: Infertility
Intervention:
Outcome Measures: Frequency and severity of all adverse events regardless of the causal relationship to Pergoveris®;   Clinical pregnancy;   Percentage of patients with more than one follicle greater than 17mm on day of human chorionic gonadotrophin (HCG) administration
6 Recruiting A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Condition: Thyroid Neoplasm
Intervention: Drug: Valproic Acid
Outcome Measures: To determine if valproic acid will inhibit thyroid cancer growth, as evidenced by a decrease in thyroglobulin level, and tumor size.;   To determine if valproic acid therapy will induce differentiation of and therefore increase uptake of radioactive iodine by the tumor cells. To determine the effect of valproic acid on differentiation markers.
7 Recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)
Condition: Infertility
Interventions: Drug: Pergoveris®;   Drug: GONAL-f®;   Drug: Recombinant human chorionic gonadotrophin (r-hCG)
Outcome Measures: Total number of retrieved oocytes;   Ongoing pregnancy rate;   Live birth rate;   Embryo implantation rate;   Clinical pregnancy rate;   Biochemical pregnancy rate
8 Unknown  Comparison of Iodine-124 (I-124) and Iodine-131 (I-131) Radiopharmacokinetics
Condition: Thyroid Cancer
Intervention: Radiation: Radioactive Iodine 124
Outcome Measure: Compare the measurement of radioiodine uptake and clearance in suspected metastatic foci of well-differentiated thyroid cancer
9 Recruiting Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?
Condition: Low Risk Differentiated Thyroid Cancer
Interventions: Drug: rhTSH stimulation;   Drug: I131;   Other: Follow up
Outcome Measures: Rate of patient without event at 3 years following randomization;   Lachrymal and Salivary Glands Toxicities;   Patient's quality of life, anxiety and fear of recurrence;   Costs of treatment and follow-up;   Rate of patients without event at 5 years following randomization;   Rate of patients without event at 3 and 5 years after randomization, according to the initial lymph node status;   Recurrence rate (histologically proven) at three years following thyroidectomy;   Rate of patients without event at 3 and 5 years after randomization, according to tumoral molecular characterization;   Future of patients experiencing en event
10 Recruiting Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism
Conditions: Kallmann Syndrome;   Idiopathic Hypogonadotropic Hypogonadism;   GnRH Deficiency
Intervention: Drug: gonadotropin releasing hormone (GnRH)
Outcome Measures: testosterone;   LH;   FSH;   Inhibin B;   free alpha subunit
11 Recruiting Baselines in Reproductive Disorders
Conditions: Amenorrhea;   Hypogonadotropic Hypogonadism;   Kallmann's Syndrome
Intervention: Procedure: Frequent baseline blood sampling
Outcome Measures: Number of luteinizing hormone (LH) and FAS (free alpha subunit) pulses;   Amplitude of LH and FAS pulses;   Inter-pulse interval for LH and FAS pulses
12 Recruiting Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Condition: Differentiated Thyroid Cancer
Interventions: Drug: Selumetinib;   Drug: Placebo;   Drug: Radioactive Iodine Therapy
Outcome Measures: Complete remission rate in overall study population;   Clinical remission rate in overall study population;   Clinical remission rate in sub-group of patients with tumours known to be mutation positive for v-raf murine sarcoma viral oncogene homolog B1 or NRAS;   Frequency of adverse events graded according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE)";   Selumetinib concentration profile over time;   N-desmethyl selumetinib concentration profile over time;   Selumetinib amide concentration profile over time;   Complete remission rate in sub-group of patients with tumours known to be mutation positive for v-raf murine sarcoma viral oncogene homolog B1 or NRAS
13 Recruiting Effects of THW and rhTSH in Glomerular Filtration Rate During RIT
Condition: Other Impaired Renal Function Disorder
Intervention: Other: rhTSH Group
Outcome Measure: Observation of differences in glomerular filtration rate with THW or rhTSH in radioiodine therapy
14 Unknown  Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Condition: Thyroid Cancer
Intervention: Drug: Recombinant thyrotropin
Outcome Measures: PET-CT fusion scanning after rTSH will be more sensitive to detect disease sites than scanning without rTSH; this information will significantly alter the therapeutic approach in some patients.;   Increase in FDG PET SUV after rTSH will be more specific for metastases than for nonneoplastic processes (e.g., infection and muscle contraction).
15 Recruiting Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
Conditions: Thyroid Cancer;   Metastases
Intervention: Drug: TSH stimulation
Outcome Measures: the 124 I uptake after TSH stimulation;   The activity of 131I that should be administered according to each TSH stimulation method;   Radiation exposure of the blood
16 Not yet recruiting Research Examining Gulf War Illness in Our Nations Service Members
Condition: Gulf War Illness
Interventions: Drug: Duloxetine;   Drug: Pregabalin;   Drug: Placebo
Outcome Measures: Pain , Safety, tolerability;   Side Effects

These studies may lead to new treatments and are adding insight into Thyrogen etiology and treatment.

A major focus of Thyrogen research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Thyrogen